Leukemia mutation genes do not turn negative, will have a higher relapse rate than patients after the mutation genes turn negative. 1. Leukemia mutant genes can turn negative after treatment, such as WT1 gene, TP53 gene, etc. This is clinically known as complete remission at the molecular biology level, which is an objective indicator to judge the effect of leukemia treatment, and it is more accurate than the description of hematological complete remission, and reaching complete remission at the molecular biology level is closer to the indicator of complete recovery, and the patient’s prognosis will be improved after the gene turns negative. 2. On the other hand, if the mutated gene persists, it often suggests that the leukemia remission is incomplete or there may be signs of relapse, which is clinically referred to as molecular biology relapse, and the chance of hematologic relapse of the disease is extremely high if the disease is not further treated. Specific therapeutic drugs include cytarabine and Zoerythromycin. Therefore, patients with a non-transferred mutant gene have a higher relapse rate than those who have been converted. It should be noted that leukemia patients can reduce the adverse effects of the disease through “early detection, early diagnosis, early treatment”, many patients are likely to survive for a long time, it is recommended that patients to establish confidence in the treatment, under the guidance of the physician to receive treatment.